TECHNOLOGY
BUILDING THE FUTURE
Advances in medicine are unlocking ever more powerful therapeutic solutions. Current production systems for these valuable biologics are expensive as a consequence of capital-intensive facilities, extensive reagent supply-chains, and complex & costly manufacturing biochemistries.
Our ability to engineer organisms has provided unprecedented power to use biology as a manufacturing technology. Bondi has developed a novel biologic production and delivery platform that allow us to produce and deliver a range of therapeutics using engineered light-driven cyanobacteria.
STRAIN ENGINEERING
RAPID CELL-LINE ENGINEERING METHODS FOR A RANGE OF MODALITIES
Bondi has developed a world leading organism engineering platform - Cyanoworks™. Our proprietary strain engineering methods allow us to extensively engineer cyanobacteria as both the manufacturing and delivery platform for a range of therapeutic modalities.
Cyanoworks™, a world-first high-throughput cyanobacterial strain engineering platform, enabled a speed and breadth of genetic engineering of cyanobacteria strains not previously realized anywhere in the world.
We are building on the unique biological features and biochemistries of our cyanobacterial chassis strains to produce and deliver a range of complex therapeutics from nanoparticles, through nucleic acids to monoclonal antibodies.
BIOLOGIC PRODUCTION
RELIABLE & RAPID CULTIVATION & PROCESSING OF CYANOBACTERIAL CELLS UP TO INDUSTRIAL-SCALE
Our modular light and CO2-powered system rapidly, reliably and safely produce food-grade, self-formulating biologics at significantly reduced cost and complexity compared to current approaches.
We ‘grow’ large quantities of our biologics in weeks, with our cyanobacteria achieving densities exceeding traditional mammalian, insect, or plant cell culture.
Bondi has established reliable, large-scale, modular cell cultivation methods, and critical downstream processing steps to enable rapid production at scale.
THREAT-RESPONSE & DISTRIBUTED MANUFACTURING SOLUTION
The low-complexity of our manufacturing technology in combination with food-grade, needle-free delivery makes the Bondi platform ideal to counter emerging disease threats. Our platform not only facilitates rapid vaccine development, via our strain engineering capability, it enables the rapid production of very large quantities of vaccine in a distributed manner.
NEEDLE-FREE DELIVERY
For relevant applications, our food-grade cyanobacteria is well suited to needle-free delivery, either through nasal or oral methods. Unlike bacterial systems, our cyanobacteria are non-toxic and do not contain endotoxins. For oral delivery, our cyanobacteria and its tough cellulose cell wall has significant potential for self-encapsulation and self-formulation.
HIGH-VALUE INGREDIENTS
ADVANCED LIGHT AND CO2-DRIVEN BIOMANUFACTURING
The supply of in-demand and valuable compounds is increasingly threatened by environmental change, habitat destruction, and unsustainable harvesting methods. Petrochemical providers are under increasing economic, regulatory, societal and moral pressure to reduce toxic emissions and pollutants.
The ability to read and write DNA has provided unprecedented power to use biology as a manufacturing technology. We have developed a platform underpinned by proprietary methods to engineer light-driven cyanobacteria biofactories at large scale.
Our cyanobacteria strains offer fast, controllable growth, robustness and ease of genetic manipulation. We use this power to create a flexible, scalable, customisable solution to produce high-value compounds, while simultaneously capturing and utilizing carbon to create an elegant circular bioeconomy.
Our solar biomanufacturing approach produces clean and sustainable products across a range of markets including, agriculture, aquaculture, fragrances, cosmetics, flavors, food, nutraceuticals and pharmaceuticals.
